Study of the Immune Response in Colon Adenocarcinoma

Etude de la réponse Immunitaire Dans l'adénocarcinome Colique

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03015038

Acronym

IMCO

Enrollment

100

Registered

2017-01-09

Start date

2017-02-05

Completion date

2024-02-05

Last updated

2025-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon Adenocarcinoma

Brief summary

Duration of each part of the study per patient: * Screening: From 1 to 4 weeks * Sampling period (blood and tissue): 1 day * Follow-up by patient: 60 months * Total study duration by patient: 84 months * Total inclusion duration: 24 months * Total Follow-up duration: 60 months * Total study duration: 84 months

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patients aged 18 or more. 2. Affiliation to a social security scheme 3. Diagnosis of a colon adenocarcinoma. 4. Patient have signed and dated consent of the study before undertaking procedures related to the study.

Exclusion criteria

1. Patients under guardianship / curatorship 2. Following Situations * Persons unable to understand, read and / or sign an informed consent * Patient with the following functions: investigator or co-investigator, research assistant, pharmacist, study coordinator or having any involvement in the study * Uncooperative person or potentially non-compliant for the study and its procedures with predictable difficulties regular monitoring of over 1 year. * No affiliation to a social security scheme, a universal medical coverage or any similar plan. 3. Pregnant or lactating women. 4. Patients with HIV seropositivity. 5. Rectal tumor location.

Design outcomes

Primary

Measure	Time frame	Description
Immune cells trafficking	Day 0	Frequency of T cells in the blood and tissue (Flow cytometry method with a panel of Ab).

Secondary

Measure	Time frame	Description
Infiltration of leucocytes in tumor tissue	Day 0	Histochemical method with a panel of Ab.
Safety (Number of adverse events, ECOG status)	After Day 0 until the end of the study (Month 3, Month 6, Month 9, Month 12, Month 15, Month 18,Month 21, Month 24, Month 30, Month 36, Month 42, Month 48, Month 54 and Month 60)	—

Countries

France

Outcome results